Shares of Medicure Inc. (CVE:MPH – Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as C$1.34 and last traded at C$1.27, with a volume of 14300 shares traded. The stock had previously closed at C$1.29.
Medicure Price Performance
The company has a market capitalization of C$11.06 million, a P/E ratio of -8.15 and a beta of 1.09. The company’s 50-day moving average price is C$1.12 and its two-hundred day moving average price is C$1.11. The company has a debt-to-equity ratio of 4.65, a current ratio of 2.03 and a quick ratio of 1.29.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
Featured Articles
- Five stocks we like better than Medicure
- How to Invest in Biotech Stocks
- Stellantis Makes a High-Stakes Bet on Jeep
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Nuclear Energy Earnings: Which Names Won and Lost in Q3
- Election Stocks: How Elections Affect the Stock Market
- Alphabet: Buffett’s Bet on Its Next Phase of Growth
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
